Source MS Society:
A second independent review into how Personal Independence Payment (PIP) is working was published recently.
Research on Faulty Stem Cells Suggests MS Patients Need Tailored Therapies
Source Multiple Sclerosis News Today:
Brain stem cells from primary progressive multiple sclerosis (PPMS) patients lack the ability to repair brain damage and to trigger the maturation of protective myelin-producing cells, a surprising study with far-reaching implications indicates.
Cakes and help needed
Cakes needed for cake sale at Milton Park on Friday 5th May, can you either
– buy or make some cakes/cake? We need cookies, cupcakes, whole cakes, any cakes….?
– help on the stall between 11 and 2?
Amazon shopping
DisabledHolidays.com – Travel without limits
This company have been highly recommended and we wanted to share the news with you.
Ocrevus (ocrelizumab) Approved By FDA
|
|||
|
Relaxation
Source MS Trust:
Relaxation techniques are activities that generate a feeling of complete peace and calm, away from daily hassles and routines.
The Mobility Roadshow
Europe’s largest test-drive and independent mobility event.
1 – 3rd June 2017 NAEX Stoneleigh, Warickshire. Free addmission and parking. Fully accessible.
Test drive and compare the latest:
Accessible vehicles, adapted driving controls, mobility scooters, ramps, wheelchairs, hoists and innovative ideas for easier mobility and much more! Visit their website here.
First treatment licensed for primary progressive MS in the US
Source MS Society:
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US. https://www.mssociety.org.uk/ms-news/2017/03/first-treatment-licensed-primary-progressive-ms-us
NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta
Source pmlive.com:
Biogen’s new multiple sclerosis (MS) therapy should be available to NHS patients in England within three months after NICE reversed an earlier appraisal decision.
